Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
4(66.7%)
Phase 2
2(33.3%)
6Total
Phase 1(4)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07481604Phase 2Not Yet Recruiting

Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above

Role: lead

NCT06137755Phase 1Recruiting

Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above

Role: lead

NCT06147895Phase 1Completed

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Prophylactic Hepatitis B Vaccine

Role: lead

NCT04289987Phase 2Completed

A Study to Evaluate the Efficacy and Safety of Therapeutic Hepatitis B Vaccine

Role: lead

NCT02693652Phase 1Completed

A Study to Evaluate the Safety and Efficacy of Therapeutic Hepatitis B Vaccine

Role: lead

NCT02692170Phase 1Completed

A Study to Evaluate the Reactogenicity, Safety, and Immunogenicity of the Third Generation Hepatitis B Vaccine

Role: lead

All 6 trials loaded